US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

ResMed Inc. Common Stock (NY:RMD)

218.89 -2.26 (-1.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Peering Into ResMed's Recent Short Interest ↗
 
Via Benzinga
News headline image
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
From ResMed Inc.
Via GlobeNewswire
News headline image
$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
A Bullish Sign Appears On ResMed's Chart ↗
 
Via Benzinga
News headline image
ResMed Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,300 Today ↗
 
Via Benzinga
News headline image
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
News headline image
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
From ResMed Inc.
Via GlobeNewswire
News headline image
Expert Ratings for ResMed ↗
 
Via Benzinga
News headline image
$1000 Invested In ResMed 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
$100 Invested In ResMed 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗
 
Via Benzinga
News headline image
Electronic Arts, TD SYNNEX And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq index closed lower on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
From ResMed Inc.
Via GlobeNewswire
News headline image
What's Going On With ResMed Stock Today ↗
ResMed Inc (NYSE: RMD) posted Q3 profits of $247.8 million, with adjusted EPS of $1.68, up from $1.32 a year ago, beating the consensus of $1.59. Revenues increased 29% to $1.12 billion, as continued... 
Via Benzinga
News headline image
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023
Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27% 
From ResMed Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 27, 2023 ↗
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
News headline image
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Chief Administrative Officer and Global General Counsel to Retire
From ResMed Inc.
Via GlobeNewswire
News headline image
3 Incredible Growth Stocks to Buy Right Now ↗
These mid-cap growth stocks could deliver market-beating returns in 2023 and beyond. 
Via The Motley Fool
News headline image
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
From ResMed Inc.
Via GlobeNewswire
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >